GLP-1 Drugs, Compounding, and FDA Oversight: What’s Next for Ozempic, Wegovy, and Tirzepatide

GLP-1s: what they are and how they work

GLP-1 drugs mimic the body's own glucagon-like peptide-1, a hormone that stimulates insulin release and fosters satiety. The episode explains how brand names Wegovy and Ozempic use semaglutide, and Tirzepatide is sold as Zepbound and Mounjaro. Initially developed for type 2 diabetes, these drugs were repurposed for weight loss as approvals expanded in 2021, fueling a market surge that included shortages in 2022 and again in 2024-25 for other GLP-1s. Manufacturers engineered longer-acting versions to overcome the body's natural rapid breakdown of GLP-1 by enzymes, enabling effects that last about a week. The discussion clarifies the science behind why GLP-1s can reduce appetite and promote weight loss while also raising questions about long-term safety and sustainability.

"GLP-1 drugs mimic a hormone in the body called GLP-1 to boost insulin production and satiety, which helps in diabetes management and weight loss." - Lauren Young, Associate Editor, Health and Medicine, Scientific American

The rise of imitation GLP-1s and compounding

The podcast details how compounding pharmacies stepped in when official GLP-1s faced supply gaps. Ozempic and Wegovy were sometimes in short supply, and Tirzepatide (sold as Zepbound or Mounjaro) faced shortages too. Compounding pharmacies create bespoke medicines—sometimes in creams or injections with adjusted doses—for patients who cannot use standard formulations or who need intermediate dosages. While this service fills access gaps, none of these compounded GLP-1s are FDA-approved or safety-tested in the same way as brand-name versions. The episode also describes 'additives' used by compounding firms, alleged to address issues like nausea and muscle loss, though these additives lack validated safety data. Consumers may encounter lower market prices, but the safety, efficacy, and regulatory oversight differ markedly from official products.

"When shortages hit, compounding pharmacies fill the gap, but these additives and dosages are not tested for safety or effectiveness by the FDA." - Lauren Young, Associate Editor, Health and Medicine, Scientific American

FDA warning letter, lawsuits, and market dynamics

The discussion covers the February 2024 warning letter from the U.S. FDA to Novo Nordisk, alleging failure to disclose potential risks and to report on deaths among patients taking semaglutide. The company later dropped a related lawsuit against Hims & Hers, a telehealth company marketing compounded GLP-1s. The episode notes the tension between ongoing patent protections for branded GLP-1s and the expansion of compounded versions, which complicates access, pricing, and patient safety. The legal context underscores the stakes as GLP-1s move deeper into broader uses beyond diabetes and weight management.

"They sued over misbranding and copycat claims while these drugs remain under patent protection; the stakes are high for brand-name GLP-1s." - Lauren Young, Associate Editor, Health and Medicine, Scientific American

Beyond weight loss: potential benefits and long-term concerns

The segment surveys research suggesting GLP-1s might have broader health effects, including cardiovascular risk reduction and reduced inflammation, with emerging interest in applications such as treating addiction and other conditions. A Veterans Affairs study of more than 600,000 veterans found that GLP-1 use correlated with lower risk of developing substance-use disorders and, in those with existing disorders, a reduction in drug-related mortality. At the same time, clinicians warn about potential downsides: loss of lean muscle and bone (osteoporosis), unintended weight loss, and the possibility that health benefits may recede after stopping the drugs. The discussion emphasizes that many questions remain about long-term outcomes, durability of benefits, and who should be prioritized for therapy.

"Quitting a GLP-1 drug leads to weight regain and loss of cardio-metabolic benefits, often more quickly than other weight-loss strategies." - Rosalina McCoy, University of Maryland